ISPOR 2026: Health Technology Assessment Guidelines and Recommendations Across European Union Countries and the United Kingdom in Rare Disease and Paediatric Populations.

WHY IT MATTERS

If you have a rare disease or care for a child with one in Europe or the UK, these guidelines directly affect which new treatments your doctor can prescribe and whether your insurance will cover them.

Researchers presented new guidelines on how European Union countries and the United Kingdom decide whether to approve and pay for treatments for rare diseases and children's conditions. These guidelines help governments figure out if new medicines are worth the cost and provide good value for patients. The study looked at how different countries make these decisions and what factors they consider most important.

ISPOR 2026: Health Technology Assessment Guidelines and Recommendations Across European Union Countries and the United Kingdom in Rare Disease and Paediatric Populations. Authors: Bártová A, Samek J, Pinheiro V Journal: Applied health economics and health policy Published: 2026/03/01 Congress focus: rare disease economics, orphan drug pricing, value assessment, HEOR